Observational studyMedicine2017
Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects.
Observational study in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose-response meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Association between the TyG/HDL-C ratio and non-alcoholic fatty liver disease: a single-centre retrospective study.BMC gastroenterology · 2026Article
- The association of TyG-BMI with MAFLD and liver fibrosis: a cross-sectional study.Scientific reports · 2026Article
- Integrated prognostic evaluation of TyG and TyG-BMI in critically ill patients with comorbid atrial fibrillation and ischemic stroke using machine learning.BMC neurology · 2026Article
- Markers Of Insulin Resistance and Their Clinical Implications In Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Surveying the features of screening strategies for non-alcoholic fatty liver disease: A scoping review.Journal of education and health promotion · 2026Review
- Effect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis.Endocrine · 2025Article
- Impact of genetic variation in the human leptin gene promoter on metabolic dysfunction-associated steatotic liver disease risk.Archives of endocrinology and metabolism · 2025Article
- The Predictive Role of the Triglyceride/High-Density Lipoprotein Ratio and the Triglyceride-Glucose Index, Along with Anthropometric Measurements, in Diagnosing Non-Alcoholic Fatty Liver Disease in Obese Kids and Juveniles, and the Evaluation of Novel Cardiovascular Risk Markers in Pediatric NAFLD.Children (Basel, Switzerland) · 2025Article
- Predictive value of triglyceride glucose index in non-obese non-alcoholic fatty liver disease.BMJ open · 2025Observational
- Association between TyG-related parameters and NAFLD risk in Japanese non-obese population.Scientific reports · 2025Article
- Triglyceride glucose-waist circumference as a useful predictor for diabetes mellitus: a secondary retrospective analysis utilizing a Japanese cohort study.BMC endocrine disorders · 2025Article
- Understanding triglyceride glucose-body mass index: implications for diabetes and cardiovascular disease management.Frontiers in endocrinology · 2025Review
- Predictive Value of the Triglyceride-Glucose Index for Metabolic-Associated Fatty Liver Disease in Individuals with Different Metabolic Obese Phenotypes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Research status of triglyceride glucose-body mass index (TyG-BMI index).Frontiers in cardiovascular medicine · 2025Review
- The Value of TyG-Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD.Canadian journal of gastroenterology & hepatology · 2025Article
- U-shaped relationship between triglyceride glucose-body mass index and suicide attempts in Chinese patients with untreated first-episode major depressive disorder.BMC psychiatry · 2024Article
- Establishment and Evaluation of a Noninvasive Metabolism-Related Fatty Liver Screening and Dynamic Monitoring Model: Cross-Sectional Study.Interactive journal of medical research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is highly correlated with obesity; however, it is not uncommon among nonobese individuals. Triglyceride (TG) and glucose index combined with body mass index (TyG-BMI) has been proposed as a favorable marker of insulin resistance. We sought to investigate the effectiveness of TyG-BMI in identifying NAFLD in nonobese subjects.We conducted a cross-sectional study in a nonobese (BMI <25.0 kg/m) Chinese population (N = 6809) of adults who underwent health examinations, including abdominal ultrasonography.The prevalence of ultrasonography-detected NAFLD was 23.9% in nonobese subjects. After adjusting for potential confounders, every 1-standard deviation increase in TyG-BMI had an odds ratio (OR) of 3.4 [95% confidence interval (95% CI), 3.0-3.9] for NAFLD. Compared with the lowest quartile of TyG-BMI, multivariable-adjusted ORs were 2.4 (1.6-3.6), 6.4 (4.2-9.7), and 15.3 (9.8-23.9) for those in the second, third, and fourth quartile, respectively. According to the receiver operating characteristic curve analysis, TyG-BMI was effective in diagnosing patients with NAFLD with an area under the curve of 0.835 (95% CI, 0.824-0.845). In comparison, TyG-BMI was superior to its components, including TyG, BMI, TG, and fasting plasma glucose, for identifying nonobese subjects at risk for NAFLD.In this study, the prevalence of NAFLD was over one-fifth in the nonobese population. TyG-BMI was an effective marker to detect NAFLD in nonobese subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.